Barclays
CYCN

Barclays’s Cyclerion Therapeutics CYCN Stock Holding History

Barclays’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$295 Buy
+87
New +$282 ﹤0.01% 5067
2025
Q4 		– Sell
-5
Closed -$12 – 5327
2025
Q3 		$12 Buy
+5
New +$14 ﹤0.01% 5386
2021
Q4 		– Sell
-115
Closed -$7K – 4210
2021
Q3 		$7K Sell
115
-106
-48% -$6.94K ﹤0.01% 4564
2021
Q2 		$17K Sell
221
-705
-76% -$44.1K ﹤0.01% 4529
2021
Q1 		$52K Buy
926
+569
+159% +$42.7K ﹤0.01% 4188
2020
Q4 		$22K Sell
357
-152
-30% -$10.4K ﹤0.01% 4657
2020
Q3 		$62K Sell
509
-150
-23% -$17.2K ﹤0.01% 4491
2020
Q2 		$77K Buy
659
+268
+69% +$22.4K ﹤0.01% 4686
2020
Q1 		$20K Sell
391
-790
-67% -$56.4K ﹤0.01% 5641
2019
Q4 		$64K Buy
1,181
+591
+100% +$55.2K ﹤0.01% 5665
2019
Q3 		$143K Sell
590
-171
-22% -$36.9K ﹤0.01% 5199
2019
Q2 		$174K Buy
+761
New +$215K ﹤0.01% 5242

Other funds holding CYCN

KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Barclays's CYCN Position: Q2 2026 in Review

Barclays opened a new position in Cyclerion Therapeutics (CYCN) in Q2 2026: 87 shares worth $295. The stake represents ﹤0.01% of the portfolio and ranks #5067 among its holdings. This is a return to the name: Barclays previously reported a position in CYCN as recently as Q3 2025.

Barclays first reported a position in CYCN in Q2 2019 and has held it in 12 quarters since. The position peaked at $174K in Q2 2019. 21 funds tracked by Wall St. Rank hold CYCN as of Q2 2026.

  • Barclays held 87 shares of Cyclerion Therapeutics worth $295 as of Q2 2026.
  • Cyclerion Therapeutics was a new Barclays position in Q2 2026.
  • Cyclerion Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5067 holding.
  • Barclays first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 12 quarters since.
  • Barclays's Cyclerion Therapeutics position peaked at $174K in Q2 2019.
  • 21 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.